Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Bibas
Michele
M
National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.
Grisetti
Susanna
S
Alba
Lucia
L
Picchi
Giovanna
G
Del Nonno
Franca
F
Antinori
Andrea
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003561:Cytarabine / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000008:administration & dosage; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077269:Lenalidomide; D016400:Lymphoma, Large-Cell, Immunoblastic / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D008297:Male; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011092:Polyethylene Glycols; D011719:Pyrazines / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D055815:Young Adult; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D001897:Boronic Acids; D009944:Organoplatinum Compounds; D011719:Pyrazines; D011994:Recombinant Proteins; D003561:Cytarabine; D000077150:Oxaliplatin; D003841:Deoxycytidine; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide; D000069585:Filgrastim; D000093542:Gemcitabine